Genmab A/S
Genmab A/S (FWB: GE9) is trading at €312.40, about ₹34,024 at today's EUR/INR rate, as of 30 Sep 2026, 11:01 AM ET, up 1.40% today. Indian residents can buy Genmab from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
€312.40
Today's high
€312.70
52 week low
€202.40
52 week high
€312.70
GE9 opened at €312.70, closed previously at €308.10, and has traded between €202.40 and €312.70 over the past 52 weeks.
About
Genmab A/S, established in 1999 and headquartered in Copenhagen, Denmark, is a biotechnology firm specializing in the development of antibody therapeutics for cancer and various other medical conditions, primarily operating from its Danish base. The company currently offers several key therapies to the market, including DARZALEX, a human monoclonal antibody targeting multiple myeloma (MM); teprotumumab for thyroid eye disease; and Amivantamab, indicated for advanced or metastatic gastric/esophageal cancer and non-small cell lung cancer (NSCLC). Genmab's extensive product pipeline features daratumumab for MM, non-MM blood cancers, and AL amyloidosis, alongside GEN1047. Other developing treatments include tisotumab vedotin for cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for hematological malignancies. Furthermore, the company is advancing Inclacumab (currently in Phase 3 for vaso-occlusive crises), Camidanlumab tesirine (for Hodgkin lymphoma and solid tumors), JNJ-64007957 and JNJ-64407564 (for MM), PRV-015 (for celiac disease), Mim8 (for hemophilia A), and Lu AF82422 (for multiple system atrophy). Beyond these, numerous pre-clinical programs are actively underway. Genmab engages in significant strategic partnerships, including a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. It also collaborates with argenx on novel therapeutic antibody discovery and commercialization in immunology and oncology, with AbbVie for epcoritamab's development, and maintains alliances with BioNTech, Janssen, and Novo Nordisk A/S.
Key statistics
Avg. volume
16.00
Market cap
€19.21B
P/E Ratio
27.73
Price-to-sales ratio
2.26
Enterprise value
$130.56B
Free cash flow yield
0.94%
Debt-to-equity ratio
0.89
Return on equity
17.13%
ROIC
8.86%
Beta
0.69
Dividend yield
0.00%
Last dividend
€0.00
Financial overview
Revenue
$3.85B
Earnings per share
$16.04
Free cash flow
$1.19B
Net profit margin
8.17%
Gross margin
39.92%
EBITDA
$1.37B
Revenue growth
-82.11%
Similar securities
This is not an investment recommendation
How to buy Genmab from India
Indian residents can buy Genmab shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to EUR.
Search for Genmab and place an order
Find Genmab by name or by its ticker, GE9, and choose an order type. Genmab trades 11:30 am – 11:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Genmab position in EUR and INR. Genmab pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Genmab from India
Trading and taxes when buying Genmab from India
Trading and limits
- Trading hours
- 8:00 am – 8:00 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneGenmab does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Genmab stock?
Yes. Genmab (GE9) has been listed on the Frankfurt Stock Exchange since 2000, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to EUR. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Genmab share cost in rupees?
One Genmab share is €312.40 — about ₹34,024 at an EUR/INR rate of 108.91 on 29 Sep 2026. Both the Genmab price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Genmab from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Genmab shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the EUR/INR rate on the purchase and the sale date, so the rupee move counts alongside the Genmab price. Paasa issues a capital-gains statement for your return.
Does Genmab pay a dividend?
No. Genmab does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Genmab from India?
The Frankfurt Stock Exchange trades 11:30 am – 11:30 pm IST in Indian time. The window shifts to 12:30 pm – 12:30 am IST when Germany is on standard time. Orders can only execute during that window.
Is Genmab a Germany company, and does that change how it is taxed?
Genmab trades on the Frankfurt Stock Exchange in EUR, but the company is domiciled in Denmark. Genmab trades as an ordinary share listed directly in Germany, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Genmab shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Genmab holding, its cost and its closing value.
How do I sell Genmab and bring the money back to India?
You sell during market hours (11:30 am – 11:30 pm IST) and the proceeds settle in EUR in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Genmab?
Yes. Genmab is priced in EUR, so your rupee outcome combines the EUR move with the EUR/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.